title: Aspirin and Cancer.
abstract: The place of aspirin in primary prevention remains controversial, with North American and European organizations issuing contradictory treatment guidelines. More recently, the U.S. Preventive Services Task Force recommended "initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." This recommendation reflects increasing evidence for a chemopreventive effect of low-dose aspirin against colorectal (and other) cancer. The intent of this paper is to review the evidence supporting a chemopreventive effect of aspirin, discuss its potential mechanism(s) of action, and provide a conceptual framework for assessing current guidelines in the light of ongoing studies.
authors: Department of Neuroscience, Imaging and Clinical Sciences and Center of Excellence on Aging, "G. D'Annunzio" University School of Medicine, Chieti, Italy.
authors: Paola
authors: P
authors: Patrignani
authors: Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. Electronic address: carlo.patrono@rm.unicatt.it.
authors: Carlo
authors: C
authors: Patrono
mesh_terms: D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
keywords: chemoprevention; colorectal neoplasms; cyclooxygenase-1; nonsteroidal anti-inflammatory agents; platelet activation; prostaglandins